Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura-Reference-Cited by-同舟云学术

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

Published:2017-06-05 Issue:7 Volume:15 Page:1448-1452
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Peyvandi F.¹^ORCID,Scully M.²,Kremer Hovinga J. A.³,Knöbl P.⁴,Cataland S.⁵,De Beuf K.⁶,Callewaert F.⁶,De Winter H.⁶,Zeldin R. K.⁶

Affiliation:

1. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca’ Granda Ospedale Maggiore Policlinico Department of Pathophysiology and Transplantation University of Milan Milan Italy

2. Department of Haematology University College London Hospital London UK

3. University Clinic of Hematology & Central Hematology Laboratory Inselspital Bern University Hospital and Department of Clinical Research University of Bern Bern Switzerland

4. Department of Medicine 1 Division of Hematology and Hemostasis Medical University of Vienna Vienna Austria

5. Department of Internal Medicine Ohio State University Columbus OH USA

6. Ablynx NV Zwijnaarde Belgium

Funder

Ablynx

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.13716

Reference20 articles.